Table 1. Formulary coverage for injectable CGRP inhibitors by payer segment, 2020 COVERED LIVES Commercial All plans Formulary coverage Aimovig (erenumab) No* Yes Unknown but PA/QL policy available Ajovy (fremanezumab) No* Yes Unknown but PA/QL policy available Emgality (galcanezumab) No* Yes Unknown but PA/QL policy available Health Insurance Exchange N % 9,106,336 100% N 142,470,178 % 100% 4,988,494 136,007,871 3.5% 95.5% 2,677,215 6,262,492 29.4% 68.8% 1,473,814 1.0% 166,629 1.8% 18,201,755 102,045,618 12.8% 71.6% 5,132,645 3,398,886 56.4% 37.3% 22,222,806 15.6% 574,805 6.3% 6,084,281 133,560,318 4.3% 93.7% 3,217,188 5,722,519 35.3% 62.8% 2,825,579 2.0% 166,629 1.8% Number of CGRPs on formulary** None 3,451,650 2.4% 2,485,461 27.3% One 1,499,923 1.1% 284,083 3.1% Aimovig (erenumab) 1,182,810 0.8% 92,329 1.0% Ajovy (fremanezumab) 0 0.0% 0 0.0% Emgality (galcanezumab) 317,113 0.2% 191,754 2.1% Two 15,919,732 11.2% 3,002,499 33.0% Erenumab and Fremanezumab 1,449,820 1.0% 639,398 7.0% Erenumab and Galcanezumab 13,250,181 9.3% 2,363,101 26.0% Fremanezumab and Galcanezumab 1,219,731 0.9% 0 0.0% Three 121,598,872 85.4% 3,334,293 36.6% Notes: * There were two commercial plans where formulary coverage information was not available for Aimovig and Ajovy and one ** For the purpose of calculating number of CGRPs on formulary, the plans whose formulary coverage was unknown but a PA/ COVERED LIVES Medicaid N % 63,639,556 100% Medicare N 42,797,610 OVERALL ...
Purchase document to see full attachment